bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more
bioMérieux S.A (BMXMF) - Net Assets
Latest net assets as of June 2025: $3.94 Billion USD
Based on the latest financial reports, bioMérieux S.A (BMXMF) has net assets worth $3.94 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.37 Billion) and total liabilities ($1.43 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.94 Billion |
| % of Total Assets | 73.38% |
| Annual Growth Rate | 11.89% |
| 5-Year Change | 69.71% |
| 10-Year Change | 180.25% |
| Growth Volatility | 5.63 |
bioMérieux S.A - Net Assets Trend (2005–2024)
This chart illustrates how bioMérieux S.A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for bioMérieux S.A (2005–2024)
The table below shows the annual net assets of bioMérieux S.A from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.21 Billion | +12.23% |
| 2023-12-31 | $3.75 Billion | +3.00% |
| 2022-12-31 | $3.64 Billion | +14.75% |
| 2021-12-31 | $3.17 Billion | +27.94% |
| 2020-12-31 | $2.48 Billion | +10.05% |
| 2019-12-31 | $2.25 Billion | +12.54% |
| 2018-12-31 | $2.00 Billion | +15.35% |
| 2017-12-31 | $1.74 Billion | +7.12% |
| 2016-12-31 | $1.62 Billion | +7.90% |
| 2015-12-31 | $1.50 Billion | +8.20% |
| 2014-12-31 | $1.39 Billion | +9.58% |
| 2013-12-31 | $1.27 Billion | +5.59% |
| 2012-12-31 | $1.20 Billion | +8.77% |
| 2011-12-31 | $1.10 Billion | +13.04% |
| 2010-12-31 | $976.10 Million | +21.04% |
| 2009-12-31 | $806.40 Million | +17.14% |
| 2008-12-31 | $688.40 Million | +14.49% |
| 2007-12-31 | $601.30 Million | +7.86% |
| 2006-12-31 | $557.50 Million | +11.84% |
| 2005-12-31 | $498.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to bioMérieux S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 7.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $432.20 Million | 10.28% |
| Common Stock | $12.00 Million | 0.29% |
| Other Components | $3.76 Billion | 89.44% |
| Total Equity | $4.20 Billion | 100.00% |
bioMérieux S.A Competitors by Market Cap
The table below lists competitors of bioMérieux S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fiberhome Telecommunication Technologies Co Ltd
SHG:600498
|
$5.62 Billion |
|
Shenzhen Megmeet Electrical Co Ltd
SHE:002851
|
$5.62 Billion |
|
VAXCYTE INC. DL -001
F:5VA
|
$5.63 Billion |
|
Norsk Hydro ASA
OTCQX:NHYKF
|
$5.63 Billion |
|
Taylor Morn Home
NYSE:TMHC
|
$5.61 Billion |
|
Scout24 AG
PINK:SCOTF
|
$5.61 Billion |
|
D-Wave Quantum Inc.
NYSE:QBTS
|
$5.60 Billion |
|
WT Microelectronics Co Ltd
TW:3036
|
$5.60 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in bioMérieux S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,752,200,000 to 4,204,900,000, a change of 452,700,000 (12.1%).
- Net income of 432,200,000 contributed positively to equity growth.
- Dividend payments of 100,200,000 reduced retained earnings.
- Share repurchases of 37,600,000 reduced equity.
- Other comprehensive income increased equity by 18,500,000.
- Other factors increased equity by 139,800,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $432.20 Million | +10.28% |
| Dividends Paid | $100.20 Million | -2.38% |
| Share Repurchases | $37.60 Million | -0.89% |
| Other Comprehensive Income | $18.50 Million | +0.44% |
| Other Changes | $139.80 Million | +3.32% |
| Total Change | $- | 12.06% |
Book Value vs Market Value Analysis
This analysis compares bioMérieux S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 29.80x to 3.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $4.21 | $125.44 | x |
| 2006-12-31 | $4.71 | $125.44 | x |
| 2007-12-31 | $5.07 | $125.44 | x |
| 2008-12-31 | $5.78 | $125.44 | x |
| 2009-12-31 | $6.77 | $125.44 | x |
| 2010-12-31 | $8.21 | $125.44 | x |
| 2011-12-31 | $9.26 | $125.44 | x |
| 2012-12-31 | $10.09 | $125.44 | x |
| 2013-12-31 | $10.64 | $125.44 | x |
| 2014-12-31 | $11.67 | $125.44 | x |
| 2015-12-31 | $12.62 | $125.44 | x |
| 2016-12-31 | $13.72 | $125.44 | x |
| 2017-12-31 | $14.67 | $125.44 | x |
| 2018-12-31 | $16.29 | $125.44 | x |
| 2019-12-31 | $18.57 | $125.44 | x |
| 2020-12-31 | $20.49 | $125.44 | x |
| 2021-12-31 | $26.27 | $125.44 | x |
| 2022-12-31 | $30.43 | $125.44 | x |
| 2023-12-31 | $31.58 | $125.44 | x |
| 2024-12-31 | $35.41 | $125.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently bioMérieux S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.28%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.86%
- • Asset Turnover: 0.69x
- • Equity Multiplier: 1.37x
- Recent ROE (10.28%) is below the historical average (14.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 18.09% | 9.07% | 1.10x | 1.82x | $40.28 Million |
| 2006 | 18.90% | 10.16% | 1.10x | 1.69x | $49.59 Million |
| 2007 | 16.32% | 9.22% | 1.06x | 1.66x | $37.95 Million |
| 2008 | 18.97% | 11.70% | 0.93x | 1.74x | $61.43 Million |
| 2009 | 18.43% | 12.08% | 0.97x | 1.57x | $67.62 Million |
| 2010 | 16.33% | 11.69% | 0.94x | 1.49x | $61.53 Million |
| 2011 | 14.44% | 11.08% | 0.81x | 1.61x | $48.66 Million |
| 2012 | 11.26% | 8.56% | 0.86x | 1.54x | $15.06 Million |
| 2013 | 13.03% | 10.35% | 0.72x | 1.74x | $38.22 Million |
| 2014 | 9.77% | 7.94% | 0.66x | 1.87x | $-3.19 Million |
| 2015 | 7.39% | 5.62% | 0.71x | 1.86x | $-38.95 Million |
| 2016 | 11.06% | 8.52% | 0.69x | 1.87x | $17.19 Million |
| 2017 | 13.70% | 10.41% | 0.77x | 1.72x | $64.34 Million |
| 2018 | 13.29% | 10.59% | 0.71x | 1.76x | $63.57 Million |
| 2019 | 12.38% | 10.20% | 0.71x | 1.72x | $52.41 Million |
| 2020 | 16.63% | 12.97% | 0.79x | 1.62x | $161.29 Million |
| 2021 | 19.25% | 17.80% | 0.73x | 1.48x | $288.78 Million |
| 2022 | 12.55% | 12.61% | 0.69x | 1.44x | $91.98 Million |
| 2023 | 9.53% | 9.73% | 0.70x | 1.40x | $-17.62 Million |
| 2024 | 10.28% | 10.86% | 0.69x | 1.37x | $11.71 Million |
Industry Comparison
This section compares bioMérieux S.A's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $867,957,363
- Average return on equity (ROE) among peers: -141.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| bioMérieux S.A (BMXMF) | $3.94 Billion | 18.09% | 0.36x | $5.61 Billion |
| Agilent Technologies Inc (A) | $4.57 Billion | 6.91% | 0.87x | $31.45 Billion |
| Amer Bio Medica (ABMC) | $-944.00K | 0.00% | 0.00x | $3.55K |
| ADCNF (ADCNF) | $612.34 Million | 111.18% | 6.93x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.64 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $4.37 Million | -93.77% | 0.93x | $36.19K |
| Avricore Health Inc (AVCRF) | $3.35 Million | -65.62% | 0.06x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $4.67 Million | -153.12% | 0.85x | $664.47K |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $48.86 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |